Objective-Increased production of intestinal triglyceride-rich lipoproteins (TRLs) contributes to dyslipidemia and increased risk of atherosclerotic cardiovascular disease in insulin resistance and type 2 diabetes. We have previously demonstrated that enteral glucose enhances lipid-stimulated intestinal lipoprotein particle secretion. Here, we assessed whether glucose delivered systemically by intravenous infusion also enhances intestinal lipoprotein particle secretion in humans. Approach and Results-On 2 occasions, 4 to 6 weeks apart and in random order, 10 healthy men received a constant 15hour intravenous infusion of either 20% glucose to induce hyperglycemia or normal saline as control. Production of TRL-apolipoprotein B48 (apoB48, primary outcomes) and apoB100 (secondary outcomes) was assessed during hourly liquid-mixed macronutrient formula ingestion with stable isotope enrichment and multicompartmental modeling, under pancreatic clamp conditions to limit perturbations in pancreatic hormones (insulin and glucagon) and growth hormone. Compared with saline infusion, glucose infusion induced both hyperglycemia and hyperinsulinemia, increased plasma triglyceride levels, and increased TRL-apoB48 concentration and production rate (P<0.05), without affecting TRL-apoB48 fractional catabolic rate. No significant effect of hyperglycemia on TRL-apoB100 concentration and kinetic parameters was observed.
T riglyceride-rich lipoprotein (TRL) particle secretion by both the liver (apolipoprotein B100 [apoB100]-containing very low-density lipoprotein [VLDL] ) and intestine (apoB48-containing chylomicron) is increased in insulin resistance, obesity, type 2 diabetes mellitus (T2D), and the metabolic syndrome. [1] [2] [3] ApoB48-containing lipoproteins account for the majority of postprandial rise in plasma triglyceride but are only a minor contributor to the rise in total TRL particle numbers. 4, 5 However, the atherogenic potential of chylomicrons and their remnants may be significant because they are rich in cholesterol, more readily deposited into subendothelial space and atherosclerotic plaques, and compete with VLDL for clearance. [6] [7] [8] As such, there have been increased interests in understanding the regulation of intestinal lipoprotein production in recent years. Studies from our group and others have demonstrated that a variety of endogenous and exogenous factors regulate TRL production by the intestine, as was previously known for hepatic TRL secretion. 9 One interesting finding, that is analogous to the finding in this study, was that elevated plasma free fatty acids (FFAs) and not just luminal lipids stimulate chylomicron secretion, shown in both Syrian Golden hamsters and humans. 10, 11 It has long been recognized that high carbohydrate diets and refined sugars exacerbate postprandial lipid responses and promote metabolic abnormalities. [12] [13] [14] [15] High dietary carbohydrates promote fasting and postprandial hypertriglyceridemia during chronic and some, but not all, acute studies. 15 Such effects were mostly attributed to increased VLDL secretion, with increased triglyceride and in some studies increased apoB production, along with impaired clearance. 15 However, recent evidence suggests that TRL secretion from the intestine also responds to carbohydrates. Furthermore, a single glucose drink is able to release intestinal lipid storage originating from an earlier meal. 16 In previous studies, we have demonstrated that coinfusion of monosaccharides (either glucose or fructose) with lipid emulsion directly into the duodenum promotes TRL particle production during 10-hour kinetic studies. 17 Although enteral sources of simple sugars may directly stimulate chylomicron particle production in intestinal enterocytes, they also elevated circulating levels of glucose. In this current experiment, we tested the hypothesis that intravenous glucose infusion, with its associated elevation in circulating glucose level, is capable of stimulating intestinal (and possibly) hepatic lipoprotein particle production in humans.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

Intravenous Infusion of Glucose Achieved Hyperglycemia
Constant intravenous infusion of glucose led to higher plasma glucose levels compared with infusion of normal saline during the first 3 hours, that is before the pancreatic clamp (glu-cose=6.77±0.37 versus saline=5.91±0.18 mmol/L, P<0.05; Figure 1B ). After the initiation of the clamp, glucose infusion elevated plasma glucose levels to ≈13 mmol/L at the start of the lipoprotein kinetic study. Plasma glucose gradually declined thereafter to ≈8.5 mmol/L at the end of the study. Plasma glucose increased to ≈9 mmol/L with saline infusion during the first 2 hours of the initiation of the pancreatic clamp with consequent change in insulin/glucose ratio. They were in the range of 6.5 to 8 mmol/L during the lipoprotein kinetic study. As a result, the experimental design achieved a difference in plasma glucose levels of 2 to 5 mmol/L (P<0.05) for the study duration. Incremental area under the curve for plasma glucose was significantly higher in glucose than saline (P<0.01). Plasma insulin concentrations were elevated from basal in both treatments during the pancreatic clamp, with mean insulin concentration higher with glucose infusion than with saline infusion (glucose=73.2±8.1 versus saline=43.3±3.9 pmol/L, P<0.05; Figure 1C ). This was likely because of hyperglycemia-induced stimulation of insulin secretion, as indicated by increased C-peptide concentrations with glucose ( Figure I in the online-only Data Supplement), overcoming the somatostatin-induced suppression of insulin secretion. Plasma glucagon concentrations were not significantly different between treatments (P=NS; Figure 1D ).
Intravenous Infusion of Glucose Increased Plasma Triglyceride and Decreased Plasma FFA
Plasma triglyceride was higher with glucose infusion compared with saline during the study period (glucose=1.20±0.15 versus saline=1.08±0.18 mmol/L, P<0.05; Figure 2A ). The difference in plasma triglyceride between treatments became evident starting at 4 hours and remained relatively small, likely because of the moderate degree of hyperglycemia achieved with intravenous glucose infusion. Plasma FFA levels transiently increased before the kinetic study and declined thereafter in both treatments, possibly because of the changes in insulin levels as a result of combined glucose infusion and pancreatic clamp. Plasma FFA levels were significantly lower with glucose infusion compared with saline (P<0.01; Figure   2B ), likely because of suppression of adipose lipolysis by the hyperinsulinemia with glucose infusion. TRL-triglyceride tended to be higher with glucose infusion than with saline but did not reach statistical significance because of interindividual variations (P=0.17; Figure 2C ). Because triglyceride levels in both plasma and TRL seemed to diverge between treatments after 4 hours, TRL from t=4 to 10 hours were separated into chylomicrons and VLDL by ultracentrifugation. Mean triglyceride in both chylomicrons (glucose=0.05±0.01 versus saline=0.04±0.01 mmol/L, P<0.05) and VLDL (glu-cose=0.23±0.04 versus saline=0.18±0.04 mmol/L, P<0.05) during this study period were higher with glucose infusion than with saline. No significant differences in TRL-triglyceride fractional catabolic rates (FCRs) or production rates (P=NS for both) were observed between treatments ( Figure 2D ).
Hyperglycemia With Hyperinsulinemia Did Not Significantly Affect TRL-apoB100 Concentrations, Fractional Catabolic Rate, or Production Rate
TRL-apoB100 concentrations during the study were not significantly different between glucose and saline treatments ( Figure 3A ). TRL-apoB100 FCR were calculated from stable isotopic enrichment time course curves ( Figure IIA in the online-only Data Supplement). Both FCR (glucose=3.96±0.50 versus saline=3.94±0.26 pools/d, P=NS) and production rate (glucose=10.04±1.95 versus saline=9.66±1.48 mg/kg/d, P=NS) were not statistically significant between glucose and saline treatments ( Figure 3B ).
Hyperglycemia Elevated TRL-apoB48 Concentrations by Increasing Production Rate
TRL-apoB48 concentrations increased from fasting levels with constant feeding before the start of the kinetic study (t=0), and declined thereafter in both treatments, likely because of the infusion of somatostatin. Because the experimental conditions (including use of pancreatic clamp and constant feeding) were identical in the 2 treatments arms, any potential influence on TRL-apoB48 is expected to be the same for both treatment arms; therefore, the difference in TRL-apoB48 levels is attributed to the treatments, that is intravenous infusion of glucose versus normal saline. Despite the gradual decline with saline infusion, TRL-apoB48 levels were not below fasting levels even at the end of the study (t=10 hours) with hourly ingestion of the liquid formula. Mean TRL-apoB48 concentrations during the kinetic study period were higher with glucose infusion when compared with saline (glucose=5.80±1.78 versus saline=4.03±1.50 mg/L, P<0.05; Figure 3C ). The difference between treatments was more apparent during the last 5 hours of the study, such that at the end of the infusion TRL-apoB48 concentrations were ≈2fold higher in glucose than in saline. TRL-apoB48 FCR, calculated from stable isotopic enrichment time course curves ( Figure IIB in the online-only Data Supplement) were similar in both groups (glucose=1.74±0.24 versus saline=1.78±0.32 pools/d, P=NS). TRL-apoB48 production rates, the primary outcomes, were 47% higher with glucose infusion compared with saline (glucose=0.46±0. 16 production, which despite individual variation reached statistical significance by paired t test (P<0.05; Figure 3D ).
Discussion
In previous studies, we have shown that glucose delivered into the duodenum enhances lipid-stimulated chylomicron secretion. This study provides direct experimental evidence that intravenous glucose and its associated hyperglycemia, despite concurrent hyperinsulinemia, acutely stimulates intestinal lipoprotein particle secretion in humans, adding a further dimension to intestinal lipoprotein secretion in response to glucose. The magnitude of enhanced apoB48 production by hyperglycemia (44% increase compared with saline control), the primary outcome, in this study was less than that seen previously with enteral glucose (≈6-fold). 17 One possible interpretation is that stimulation by glucose is stronger from the luminal side than from the basolateral side of the enterocyte. There are, however, several factors that should be considered in interpreting these results. In the present experimental setting, besides the difference in glycemic levels between treatment arms, glucose infusion also led to higher plasma insulin and lower plasma FFA concentrations, likely because of glucose-stimulated insulin secretion and insulin suppression of adipose tissue lipolysis. The resulting hyperinsulinemia (≈80 pmol/L) with glucose infusion was not quantitatively large. Nevertheless, both insulin and FFA are important regulators of TRL production, where insulin acutely inhibits while FFA stimulates TRL particle production. 10, 18 Despite the rise in insulin and the suppression in FFA levels, both of which would be expected to reduce intestinal TRL particle secretion, 10,18 thereby having an opposite and offsetting effect on glucose-stimulated TRL-apoB48 secretion, the net effect of intravenous glucose infusion on intestinal particle production was positive. Had insulin and FFA concentrations been identical between treatments, the magnitude of the intravenous glucose-induced rise in TRL-apoB48 production should have been larger. These results therefore exclude the possibility that circulating glucose stimulates TRL-apoB48 production via modulating insulin and FFA levels. Secretion of preformed chylomicron has been shown to occur following various stimuli, such as oral glucose, 16 sham feeding, 19 mixed meal, 20 and in our own study glucagon-like peptide (GLP)-2. 21 Release of preformed chylomicrons would cause lower stable isotopic enrichment of TRL-apoB48. In this study, TRL-apoB48 stable isotopic enrichments were similar between treatments, suggesting that release of preformed chylomicron by intravenous glucose, if any, was not greater than by saline during the kinetic study. Gut hormones GLP-1 and GLP-2 are known to affect intestinal lipoprotein secretion 22 and GLP-2 rapidly promotes the release of preformed chylomicron. 21 Because GLP-2 cosecretes with GLP-1 on a 1:1 molar ratio 23 and GLP-1 secretion is stimulated by luminal but not vascular glucose, 24 it is unlikely that GLP-1 or GLP-2 played a significant role in this study. An additional consideration is that in this study subjects ingested a liquid formula that contained both lipid and carbohydrates, whereas in the previous enteral glucose study Intralipid (containing no carbohydrate) was delivered. Inclusion of carbohydrates in the hourly ingested liquid formula may have contributed to the minor elevation in blood glucose in the control arm and the relatively small difference in glycemic levels between treatments (2-4 mmol/L between 3 and 10 hours). This may have diminished the difference in effects on apoB48 production between treatments. Furthermore, the difference in apoB48 concentration occurs late and yet plasma glucose level with intravenous glucose infusion was only modestly higher than with normal saline infusion during the last few hours of the study. This indicates that TRL-apoB48 production responds to elevation in plasma glucose but the response may not be directly proportional to plasma glucose level. Alternatively, the stimulation in TRL-apoB48 production by intravenous glucose is a relatively slow process that takes time to manifest. A slow process implies that glucose may indirectly affect chylomicron production through mechanisms beyond lipoprotein biosynthesis in the enterocytes, arguing against a direct role of glucose on intracellular lipoprotein biosynthesis and assembly.
No stimulation of hepatic TRL-apoB100 particle production was observed in this study. Adiels et al 25 demonstrated a correlation between VLDL1-apoB and hyperglycemia in patients with T2D in the fasted state. Lipoprotein production from the intestinal source was not examined in that study. This study examined the effects of a short-term (15 hours) elevation of glucose levels in the fed state, which may have different mechanisms from correlations in cross-sectional observations where hyperglycemia may have been present for many years. VLDL1-apoB production also correlated with other metabolic parameters, such as insulin resistance (homeostatic model assessment-insulin resistance), in T2D patients with dyslipidemia, 25 whereas in our study participants were healthy, nondiabetic, and normolipidemic (Table) . Increased insulin and decreased FFA levels in this study also might have contributed to the lack of effects on TRL-apoB100. Chronic consumption of high carbohydrate diets induces fasting and postprandial hypertriglyceridemia. 13 Although most carbohydrate feeding studies documented increases in VLDL-triglyceride (determining particle size), 26, 27 the effects on VLDL-apoB (particle number) were equivocal. In some studies, VLDL-apoB100 was found to be increased because of lower conversion of VLDL-apoB to LDL-apoB without significant effect on VLDL-apoB secretion 28 or because of both increased production and decreased removal. 29 Other studies have demonstrated dissociated responses of VLDL-triglyceride and apoB100 to high-carbohydrate diet, thus hypertriglyceridemia was not accompanied by increased VLDL-apoB production. 30, 31 It remains to be seen whether prolonged hyperglycemia per se stimulates TRL particle production from the liver. The increase in plasma triglyceride in response to intravenous glucose during the late part of the study (t=4-10 hours) was accounted for by increases in triglyceride content in both VLDL and chylomicron fractions. The concordant changes in triglyceride and apoB48 in chylomicron, in contrast to the changes in VLDLtriglyceride and VLDL-apoB100, further suggest a differential effect of intravenous glucose on the intestine and liver. Enteral glucose increased TRL-apoB48 FCR, 17 whereas intravenous glucose infusion in this study did not influence apoB48 clearance. The change in apoB48 clearance in response to enteral glucose may not be a result of hyperglycemia because enteral fructose stimulated apoB48 production without affecting FCR, despite induction of hyperglycemia. 17 It has been shown that glucose stimulates apoC-III expression in vitro, and plasma apoC-III concentrations correlate with fasting glucose and glucose excursion after oral glucose load in overweight patients. 32 In this study in healthy individuals, plasma apoC-III concentrations (saline=31.7±5.4 versus glucose=38.3±7.2 mg/L at t=0 and saline=33.6±7.6 versus glucose=40.4±7.2 mg/L at t=10 hours, P=NS) were not increased with short-term hyperglycemia, which is in agreement with the lack of significant differences in TRL-triglyceride and apoB48 clearance between treatments. In addition, enteral glucose delivery stimulated TRL-apoB48 production more dramatically without affecting apoC-III concentrations. 17 The mechanism whereby intravenous or enteral glucose enhances TRL-apoB48 production remains unknown. It is intuitive to speculate that glucose directly stimulated chylomicron production. One potential mechanism is that higher glucose enhanced de novo lipogenesis in the enterocytes, which provided lipid substrate for chylomicron production. De novo lipogenesis in the small intestine has been shown to occur in animal models. 33, 34 This study did not directly measure intestinal de novo lipogenesis. TRL-triglyceride turnover during the entire study period was not significantly affected by intravenous glucose infusion when compared with saline infusion. In humans, de novo lipogenesis is a quantitatively minor mechanism for development of hypertriglyceridemia with carbohydrate consumption that requires at least several days of overfeeding. 35 Therefore, de novo lipogenesis is unlikely to have played a major role in this short-term study. Crosstalk between carbohydrate and lipid metabolism is known to occur in enterocytes. For example, culture of Caco-2/15 cells with high levels of glucose promoted cholesterol uptake, enhanced the expression of the cholesterol transporter NPC1L1 and CD36, and modulated several transcription factors (eg, increased LXRα, LXRβ, PPARβ, PPARγ and ChREBP, and decreased expression of SREBP-2). 36, 37 Many of these molecular factors are also involved in chylomicron synthesis and secretion in the intestine. For example, treatment for 2 weeks with ezetimibe, an NPC1L1 inhibitor, suppressed TRL-triglyceride and apoB48 secretion in hamsters fed a high-fructose and high-fat diet. 38 Whether oral ezetimibe can abrogate the enhancement of chylomicron production by intravenous glucose in the acute settings of this study in humans is unknown. ChREBP is expressed in the small intestine, 39 potentially serving as a link between glucose and lipid metabolism in the enterocytes. LXR also senses glucose and integrates glucose and lipid metabolism in the liver. 40 The role of LXR in TRL synthesis in the intestine in response to glucose has not been examined yet. More importantly, stimulation of cholesterol uptake by high glucose concentration is because of the presence of glucose at the basolateral (corresponding to blood circulation) side of the enterocytes. 36 This study further supports that hyperglycemia (ie, elevated glucose from the basolateral side) may modulate intracellular events involved in chylomicron synthesis and secretion in the enterocytes.
The pathophysiological implications of the findings should be interpreted in the context of several limitations of this study. First, metabolic abnormalities in TRL metabolism are closely related to the development of insulin resistance. The subjects in this study had normal insulin sensitivity, as indicated by homeostatic model assessment-insulin resistance. Second, the use of continuous feeding, intravenous glucose infusion, and a pancreatic clamp represent a nonphysiological, controlled, experimental setting. Hormones used in this protocol, alone or in combination, may have unintended effects on metabolism. Third, the sample size is small. The increased TRL-apoB48 production in this study was observed with experimentally raised plasma glucose level that meets the diagnostic criteria of diabetes mellitus, which implies that hyperglycemia may contribute to the development of dyslipidemia in patients with diabetes mellitus. However, dyslipidemia may occur in the absence of hyperglycemia, which suggests that hyperglycemia-stimulated intestinal lipoprotein production is not a universal mechanism for the development of dyslipidemia. It remains unknown whether intestinal lipoprotein production is increased in other conditions of hyperglycemia, for example when hyperglycemia is found in combination with an elevation of plasma FFAs, as may be the case in those with T2D. Future studies are needed to examine the effects of hyperglycemia on TRL production under physiological conditions in individuals with insulin resistance or T2D.
In conclusion, these results demonstrate that intravenous glucose administration and consequent hyperglycemia may be pathologically linked to hyperlipidemia through enhancement of intestinal lipoprotein production. This new finding adds to the current body of knowledge that the intestinal lipoprotein production contributes to hypertriglyceridemia by responding to systemic metabolic cues in humans.
